Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.

TitleEarly-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.
Publication TypeJournal Article
Year of Publication2015
AuthorsMilner, JD, Vogel, TP, Forbes, L, Ma, CA, Stray-Pedersen, A, Niemela, JE, Lyons, JJ, Engelhardt, KR, Zhang, Y, Topcagic, N, Roberson, EDO, Matthews, H, Verbsky, JW, Dasu, T, Vargas-Hernandez, A, Varghese, N, McClain, KL, Karam, LB, Nahmod, K, Makedonas, G, Mace, EM, Sorte, HS, Perminow, G, V Rao, K, O'Connell, MP, Price, S, Su, HC, Butrick, M, McElwee, J, Hughes, JD, Willet, J, Swan, D, Xu, Y, Santibanez-Koref, M, Slowik, V, Dinwiddie, DL, Ciaccio, CE, Saunders, CJ, Septer, S, Kingsmore, SF, White, AJ, Cant, AJ, Hambleton, S, Cooper, MA
JournalBlood
Volume125
Issue4
Pagination591-9
Date Published2015 Jan 22
ISSN1528-0020
KeywordsAdolescent, Adult, Autoimmune Diseases, Child, Child, Preschool, Female, Genetic Diseases, Inborn, Humans, Infant, Lymphoproliferative Disorders, Male, Mutation, Phosphorylation, STAT1 Transcription Factor, STAT3 Transcription Factor, STAT5 Transcription Factor, T-Lymphocytes, Regulatory
Abstract

Germline loss-of-function mutations in the transcription factor signal transducer and activator of transcription 3 (STAT3) cause immunodeficiency, whereas somatic gain-of-function mutations in STAT3 are associated with large granular lymphocytic leukemic, myelodysplastic syndrome, and aplastic anemia. Recently, germline mutations in STAT3 have also been associated with autoimmune disease. Here, we report on 13 individuals from 10 families with lymphoproliferation and early-onset solid-organ autoimmunity associated with 9 different germline heterozygous mutations in STAT3. Patients exhibited a variety of clinical features, with most having lymphadenopathy, autoimmune cytopenias, multiorgan autoimmunity (lung, gastrointestinal, hepatic, and/or endocrine dysfunction), infections, and short stature. Functional analyses demonstrate that these mutations confer a gain-of-function in STAT3 leading to secondary defects in STAT5 and STAT1 phosphorylation and the regulatory T-cell compartment. Treatment targeting a cytokine pathway that signals through STAT3 led to clinical improvement in 1 patient, suggesting a potential therapeutic option for such patients. These results suggest that there is a broad range of autoimmunity caused by germline STAT3 gain-of-function mutations, and that hematologic autoimmunity is a major component of this newly described disorder. Some patients for this study were enrolled in a trial registered at www.clinicaltrials.gov as #NCT00001350.

DOI10.1182/blood-2014-09-602763
Alternate JournalBlood
PubMed ID25359994
PubMed Central IDPMC4304103
Grant ListU54 HG006542 / HG / NHGRI NIH HHS / United States
U19 HD077693 / HD / NICHD NIH HHS / United States
T32 AR007279 / AR / NIAMS NIH HHS / United States
U54 HG003273 / HG / NHGRI NIH HHS / United States
/ / Intramural NIH HHS / United States
P30 AR048335 / AR / NIAMS NIH HHS / United States
P30 CA091842 / CA / NCI NIH HHS / United States
UL1 TR000448 / TR / NCATS NIH HHS / United States
KL2 TR001448 / TR / NCATS NIH HHS / United States